Press release Biocartis Group NV: Biocartis Obtains ISO 27001 Certification for Information Security Management
24 August 2022 - 07:00AM
Press release Biocartis Group NV: Biocartis Obtains ISO 27001
Certification for Information Security Management
PRESS RELEASE: 24 August 2022, 07:00 CEST
Biocartis Obtains ISO 27001
Certification
for Information Security
Management
Mechelen, Belgium, 24
August 2022 – Biocartis Group NV (the
‘Company’ or ‘Biocartis’), an innovative molecular diagnostics
company (Euronext Brussels: BCART), today announces it has obtained
the ISO 27001 certification for the design, development,
maintenance, service provision and support of the Idylla™ platform
and associated customer-facing software.
Commenting on the obtaining of the ISO
27001 certification, Herman Verrelst, Chief Executive Officer of
Biocartis, said: “Our Idylla™ products aim to enable
universal access to personalized medicine for patients around the
world by making molecular testing actionable, convenient, fast and
suitable for any lab. The correct processing of data is a crucial
component in this. We are very proud to have obtained this ISO
27001 certification. It confirms that we treat the patient data of
our customers-labs in the Idylla™ ecosystem with utmost care, shows
the strength of our data security and ensures that our Idylla™
products will grow even more reliable and secure in the
future.”
ISO 27001 is the International Standard for the
management of information security and requires the adoption of an
information security management system (ISMS). Biocartis was
awarded the ISO certification from Brand Compliance, an
independent, third-party auditor accredited to perform ISO 27001
certifications.
The scope includes Biocartis’ Belgian and US
offices and relates to its commercial products, services and
support. As such, both Biocartis’ cloud production environments
used by customers and partners (‘primary assets’) is covered, as
well as Biocartis’ office infrastructure such as its network,
systems, devices and applications (‘supporting assets’).
--- END ---
More information:
Renate DegraveHead of Corporate Communications
& Investor Relations
Biocartise-mail rdegrave@biocartis.comtel
+32 15 631 729
mobile +32 471 53 60 64
About Biocartis
Biocartis (Euronext Brussels: BCART) is an
innovative molecular diagnostics (MDx) company providing next
generation diagnostic solutions aimed at improving clinical
practice for the benefit of patients, clinicians, payers and
industry. Biocartis' proprietary MDx Idylla™ platform is a fully
automated sample-to-result, real-time PCR (Polymerase Chain
Reaction) system that offers accurate, highly reliable molecular
information from virtually any biological sample in virtually any
setting. Biocartis is developing and marketing a continuously
expanding test menu addressing key unmet clinical needs, with a
focus in oncology, which represents the fastest growing segment of
the MDx market worldwide. Today, Biocartis offers tests supporting
melanoma, colorectal and lung cancer, as well as for COVID-19, Flu,
RSV and sepsis. More information: www.biocartis.com. Follow us
on Twitter: @Biocartis_.
Biocartis and Idylla™ are registered trademarks
in Europe, the United States and other countries. The Biocartis and
Idylla™ trademark and logo are used trademarks owned by Biocartis.
Please refer to the product labeling for applicable intended uses
for each individual Biocartis product.
This press release is not for distribution,
directly or indirectly, in any jurisdiction where to do so would be
unlawful. Any persons reading this press release should inform
themselves of and observe any such restrictions. Biocartis takes no
responsibility for any violation of any such restrictions by any
person. This press release does not constitute an offer or
invitation for the sale or purchase of securities in any
jurisdiction. No securities of Biocartis may be offered or sold in
the United States of America absent registration with the United
States Securities and Exchange Commission or an exemption from
registration under the U.S. Securities Act of 1933, as amended.
Forward-looking statements
Certain statements, beliefs and opinions in this
press release are forward-looking, which reflect the Company's or,
as appropriate, the Company directors' or managements' current
expectations and projections concerning future events such as the
Company's results of operations, financial condition, liquidity,
performance, prospects, growth, strategies and the industry in
which the Company operates. By their nature, forward-looking
statements involve a number of risks, uncertainties, assumptions
and other factors that could cause actual results or events to
differ materially from those expressed or implied by the
forward-looking statements. These risks, uncertainties, assumptions
and factors could adversely affect the outcome and financial
effects of the plans and events described herein. A multitude of
factors including, but not limited to, changes in demand,
competition and technology, can cause actual events, performance or
results to differ significantly from any anticipated development.
Forward-looking statements contained in this press release
regarding past trends or activities are not guarantees of future
performance and should not be taken as a representation that such
trends or activities will continue in the future. In addition, even
if actual results or developments are consistent with the
forward-looking statements contained in this press release, those
results or developments may not be indicative of results or
developments in future periods. No representations and warranties
are made as to the accuracy or fairness of such forward-looking
statements. As a result, the Company expressly disclaims any
obligation or undertaking to release any updates or revisions to
any forward-looking statements in this press release as a result of
any change in expectations or any change in events, conditions,
assumptions or circumstances on which these forward-looking
statements are based, except if specifically required to do so by
law or regulation. Neither the Company nor its advisers or
representatives nor any of its subsidiary undertakings or any such
person's officers or employees guarantees that the assumptions
underlying such forward-looking statements are free from errors nor
does either accept any responsibility for the future accuracy of
the forward-looking statements contained in this press release or
the actual occurrence of the forecasted developments. You should
not place undue reliance on forward-looking statements, which speak
only as of the date of this press release.
Biocartis Group NV (EU:BCART)
Historical Stock Chart
Von Feb 2024 bis Mär 2024
Biocartis Group NV (EU:BCART)
Historical Stock Chart
Von Mär 2023 bis Mär 2024